Antioxidant Treatment Strategies-Photobiomodulation Therapy in Diseases

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 10706

Special Issue Editors


E-Mail Website
Guest Editor
Department of Surgical Sciences and Integrated Diagnostics, Laser Centre Therapy, University of Genoa, 16132 Genoa, Italy
Interests: laser therapy; photobiomodulation; restorative dentistry; dental implantology
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
1. Department of Restorative Dental Sciences, UCL-Eastman Dental Institute, Medical Faculty, London WC1E 6DE, UK
2. Department of Surgical Sciences and Integrated Diagnostics, Laser Centre Therapy, University of Genoa, 16132 Genoa, Italy
Interests: laser therapy; photobiomodulation; laser–tissue/matter interaction; oral surgery; oral medicine and pathology; orofacial and neuropathic pain; bone regeneration; suppotive care for cancer; neurorehabilitation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The human antioxidant system works as a complex unit to regulate reactive oxygen species (ROS). Cellular antioxidant defenses usually maintain ROS/reactive nitrogen species (RNS) at concentrate level, preventing the excess oxidation of cellular molecules. Mitochondrial dysfunction can result in a reduction in the synthesis of high-energy molecules such as adenosine triphosphate (ATP). Given the crucial role of the mitochondrial organelle, organs and tissues require effective antioxidant therapy to illuminate the mitochondria to augment ATP production and regulate ROS and nitric oxide (NO) to restore mitochondrial function. In this context, photobiomodulation therapy has emerged in the management of various mitochondrial dysfunction diseases/conditions and adverse effects resulting from various oncology treatments, in terms of pain alleviation and tissue regeneration and viral load in coronavirus-19 disease.

The aim of this Special Issue is to underline the advances of photobiomodulation and cutting-edge antioxidants strategies in the fields of medicine and dentistry, as a therapeutic or/and preventive treatment modality.

Both original research papers and review papers are welcome. Technical topics include but are not limited to the following:

  • Advanced understanding of photobiomodulation mechanism as an antioxidant at cellular level;
  • Photobiomodulation in neurological, musculoskeletal, and endocrinological diseases and disorders;
  • Effects of photobiomodulation on accelerating acute and chronic wound healing;
  • Photobiomodulation therapy in pain management;
  • Role of light therapy in dental and oral diseases;
  • Photobiomodulation therapy and its influence on dental implant integration;
  • Influence of photobiomodulation therapy in bone healing and regeneration of various bone defects;
  • Impact of photobiomodulation on mitochondrial dysfunction conditions/diseases;
  • Photobiomodulation therapy and its role in orofacial neuropathic pain management;
  • Photobiomodulation therapy in oral mucosal lesion management;
  • Photobiomodulation in management of oncology therapies adverse effects;
  • Understanding the molecular and cellular interaction of light with organelles in various diseases management;
  • Antioxidants strategies in COVID-19 management.

Prof. Dr. Stefano Benedicenti
Prof. Dr. Reem Hanna
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • photobiomodulation
  • pain management
  • dental and oral diseases
  • tissue regeneration
  • mitochondrial dysfunction conditions/diseases
  • orofacial neuropathic pain
  • oxidative stress
  • oral mucosal lesions
  • light therapy
  • neurodegenerative diseases
  • mitochondrial biogenesis
  • oral mucositis
  • coronavirus-19 (COVID-19) diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

38 pages, 7487 KiB  
Article
A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up
by Juliette Hepburn, Susan Williams-Lockhart, René Jean Bensadoun and Reem Hanna
Antioxidants 2022, 11(11), 2211; https://doi.org/10.3390/antiox11112211 - 8 Nov 2022
Cited by 11 | Viewed by 10105
Abstract
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 virus was first recognized in late 2019 and remains a significant threat. We therefore assessed the use of local methylene blue photodynamic viral inactivation (MB-PDI) in the oral and nasal cavities, in combination with the systemic [...] Read more.
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 virus was first recognized in late 2019 and remains a significant threat. We therefore assessed the use of local methylene blue photodynamic viral inactivation (MB-PDI) in the oral and nasal cavities, in combination with the systemic anti-viral, anti-inflammatory and antioxidant actions of orally ingested methylene blue (MB) and photobiomodulation (PBM) for COVID-19 disease. The proposed protocol leverages the separate and combined effects of MB and 660nm red light emitted diode (LED) to comprehensively address the pathophysiological sequelae of COVID-19. A total of eight pilot subjects with COVID-19 disease were treated in the Bahamas over the period June 2021–August 2021, using a remote care program that was developed for this purpose. Although not a pre-requisite for inclusion, none of the subjects had received any COVID-19 vaccination prior to commencing the study. Clinical outcome assessment tools included serial cycle threshold measurements as a surrogate estimate of viral load; serial online questionnaires to document symptom response and adverse effects; and a one-year follow-up survey to assess long-term outcomes. All subjects received MB-PDI to target the main sites of viral entry in the nose and mouth. This was the central component of the treatment protocol with the addition of orally ingested MB and/or PBM based on clinical requirements. The mucosal surfaces were irradiated with 660 nm LED in a continuous emission mode at energy density of 49 J/cm2 for PDI and 4.9 J/cm2 for PBM. Although our pilot subjects had significant co-morbidities, extremely high viral loads and moderately severe symptoms during the Delta phase of the pandemic, the response to treatment was highly encouraging. Rapid reductions in viral loads were observed and negative PCR tests were documented within a median of 4 days. These laboratory findings occurred in parallel with significant clinical improvement, mostly within 12–24 h of commencing the treatment protocol. There were no significant adverse effects and none of the subjects who completed the protocol required in-patient hospitalization. The outcomes were similarly encouraging at one-year follow-up with virtual absence of “long COVID” symptoms or of COVID-19 re-infection. Our results indicate that the protocols may be a safe and promising approach to challenging COVID-19 disease. Moreover, due its broad spectrum of activity, this approach has the potential to address the prevailing and future COVID-19 variants and other infections transmitted via the upper respiratory tract. Extensive studies with a large cohort are warranted to validate our results. Full article
Show Figures

Graphical abstract

Back to TopTop